Department of Nuclear Medicine and Molecular Imaging - Institut de Cancérologie de Strasbourg Europe (ICANS), IPHC, UMR 7178, CNRS/University of Strasbourg, Strasbourg, France.
Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.
Semin Nucl Med. 2021 Sep;51(5):519-528. doi: 10.1053/j.semnuclmed.2021.03.001. Epub 2021 Apr 7.
Management of patients with neuroendocrine neoplasms (NEN) is complex and warrants referral of these patients to high volume centers with appropriate expertise to ensure favorable outcomes. PET/CT becomes increasingly important in every step of their management and outcome. The choice of radiopharmaceutical heavily depends on tumor origin, which is intimately interconnected to embryology, grade and clinical presentation (eg, diagnostic vs theranostic settings). The aim of this review is to describe the role of SSTR, F-FDOPA, and F-FDG-PET imaging in the evaluation of NEN patients. There is emphasis on the main variants, caveats, and pitfalls that can be observed within these modalities. Nuclear physicians must be equipped with the skills to handle potential variants, caveats, and pitfalls that are commonly encountered in NEN imaging, and they should understand the expected imaging features that are encountered across various types of NENs.
神经内分泌肿瘤（NEN）患者的管理非常复杂，需要将这些患者转诊到具有适当专业知识的高容量中心，以确保获得良好的结果。PET/CT 在其管理和结果的每一个步骤中都变得越来越重要。放射性药物的选择在很大程度上取决于肿瘤的起源，而肿瘤起源与胚胎学、分级和临床表现（例如，诊断与治疗性设置）密切相关。本综述的目的是描述 SSTR、F-FDOPA 和 F-FDG-PET 成像在评估 NEN 患者中的作用。重点介绍了在这些模式中可能观察到的主要变体、注意事项和陷阱。核医学医师必须具备处理在 NEN 成像中常见的潜在变体、注意事项和陷阱的技能，并且应该了解在各种类型的 NEN 中遇到的预期成像特征。
